As a pathologist working at two large medical centers, I have studied the effects of smoking on health for over 20 years. I’ve published scores of papers on the impressive benefits of switching from cigarettes to safer, non-combustible forms of tobacco (such as Swedish snus). This strategy – called tobacco harm reduction – has vast potential for improving public health.
Publishing a study of tobacco-specific nitrosamines in American smokeless tobacco products (abstracthere), Dorothy Hatsukami and colleagues at the University of Minnesota called for the FDA to issue “regulations…to reduce levels of…NNK and NNN in smokeless tobacco products to the lowest levels possible.” The authors make illogical and unscientific claims in their article and media interviews (here).
As noted previously (here), Drs. Karl Fagerström and Tom Eissenberg have described a continuum of dependence among tobacco and nicotine products. They concluded that cigarettes are the most dependence-producing (addictive) product and that smokeless tobacco is intermediate, evidenced by clinical trials showing that quitting cigarette smoking is more difficult than quitting ST.